DRUGS & MEDICAL DEVICES

The FDA informed healthcare professionals of findings from two additional clinical studies, Preoperative Epirubicin Paclitaxel Aranesp Study, and the National Cancer Institute Gynecologic Oncology Group, showing an increase in mortality and shorter time to tumor progression in patients with cancer receiving an Erythropoiesis-Stimulating Agent...

9-10-2007 A recent study found nearly 50% of patients diagnosed with Nephrogenic Systemic Fibrosis (NSF) had received an MRI involving use of a gadolinium-based contrast agent. These results were confirmed by other studies and case reports showing a similar connection between Gadolinium and NSF. NSF...

Call Now Button1-877-659-1620